1 Vardakas KZ, "Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials" 179 : 1269-1277, 2008
2 Mandell LA, "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults" 44 (44): S27-S72, 2007
3 Muhammed M, "Comparison between carbapenems and β-lactam/β-lactamase inhibitors in the treatment for bloodstream infections caused by extendedspectrum β-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis" 4 : ofx099-, 2017
4 Eliel Nham, "Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients" 대한감염학회 52 (52): 59-69, 2020
5 Fukuchi T, "Cefmetazole for bacteremia caused by ESBLproducing enterobacteriaceae comparing with carbapenems" 16 : 427-, 2016
6 Benanti GE, "Carbapenem versus cefepime or piperacillin-tazobactam for empiric treatment of bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli in patients with hematologic malignancy" 63 : e01813-e01818, 2019